Mebbe one of you longs can help me out. How do they break the blind for tumor data but keep the PFS and OS data blinded? The look at eh scans and they know who is in the control arm and who is in the treatment arm period end of story. The blind is meaningless from an FDA standpoint anyway, since ONCy will need yet another registration trial. If they cook the data well enough, they may get another bite at the apple. OS will be pretty hard to fudge though.